BofA/Merrill Lynch Downgrades Adaptimmune Therapeutics plc (ADAP) to Underperform

October 24, 2016 8:14 AM EDT
Get Alerts ADAP Hot Sheet
Price: $4.18 +0.48%

Rating Summary:
    6 Buy, 0 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 31 | New: 42
Trade ADAP Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BofA/Merrill Lynch downgraded Adaptimmune Therapeutics plc (NASDAQ: ADAP) from Neutral to Underperform.

For an analyst ratings summary and ratings history on Adaptimmune Therapeutics plc click here. For more ratings news on Adaptimmune Therapeutics plc click here.

Shares of Adaptimmune Therapeutics plc closed at $5.19 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Downgrades

Related Entities

Merrill Lynch, Bank of America

Add Your Comment